Spironolactone and hyperkalemia
This article has no abstract so we have provided the first paragraph of the full text.
The landmark Randomized Aldactone Evaluation Study (RALES), published in 1999, showed that spironolactone, a potassium-sparing diuretic, improves outcomes in patients with severe heart failure. The drug can sometimes cause life-threatening hyperkalemia, however, when used in combination with angiotensin-converting enzyme (ACE) inhibitors (which are also indicated for heart failure). Although this complication was rare in RALES, it is possible that physicians prescribe spironolactone more freely in practice. Juurlink et al. have carried out a time-series analysis to examine the effects of RALES at the population level in Ontario, Canada.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
